Clinical trials: sponsored by Almirall, S.A.
Atopic Dermatitis, Eczema
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADhope (NCT05990725)
- Testing
- Lebrikizumab
- Where
- 33 sites in Germany, Netherlands and 1 more
- Volunteers
- 260 people
- Sponsor
- Almirall, S.A.
Keratosis, Actinic
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
The purpose of the study is to evaluate the efficacy and safety of tirbanibulin 10 milligrams per gram (mg/g) ointment when applied to a treatment field (TF) larger than 25 square centimeters (cm^2) and up to 100 cm^2 in adult…
- Trial name
- TirbAKare (NCT06135415)
- Testing
- Tirbanibulin, Vehicle ointment
- Where
- 35 sites in Germany, Italy and 3 more
- Volunteers
- 280 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
The observational, non-interventional study will assess the efficacy, safety, prescription and utilization patterns of Tildrakizumab in participants with moderate to severe plaque psoriasis in routine clinical practice.
- Trial name
- SAIL (NCT04203693)
- Testing
- Tildrakizumab
- Where
- 41 sites in Austria, Belgium and 4 more
- Volunteers
- 331 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
The main aim of this study is to assess treatment satisfaction, quality of life, treatment preference, adherence and convenience, psychosocial effects of scalp psoriasis, sleep quality, and effectiveness, and safety of…
- Trial name
- PRO-SCALP (NCT05811234)
- Testing
- CAL/BDP PAD Cream
- Where
- 37 sites in Germany, Spain and 1 more
- Volunteers
- 291 people
- Sponsor
- Almirall, S.A.
Dermatitis, Atopic, Eczema
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine
The main purpose of this study is to evaluate the efficacy of lebrikizumab compared with placebo in participants not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16.
- Trial name
- ADvantage (NCT05149313)
- Testing
- Lebrikizumab
- Where
- 48 sites in Austria, Belgium and 6 more
- Volunteers
- 331 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
The purpose of the study is to assess treatment satisfaction on Day 57 in participants with Actinic Keratoses (AK) of the face or scalp following treatment with tirbanibulin ointment 1 percent (%) administered once daily for 5…
- Trial name
- NCT05741294
- Testing
- Tirbanibulin 2.5 mg ointment
- Where
- 37 sites in Italy, Spain
- Volunteers
- 334 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
The purpose of this study is to evaluate the patient-reported outcomes (PROs) in terms of health-related quality of life (HRQoL) and signs of Acne Vulgaris (AV) among patients with moderate to severe non-nodular AV who are…
- Trial name
- PROSES (NCT04820673)
- Testing
- Sarecycline
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Almirall, S.A.
Keratosis, Actinic
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
The purpose of the study is to evaluate patient reported outcomes (PROs) in terms of health-related quality of life (HRQoL) among subjects with actinic keratosis (AK).
- Trial name
- PROAK (NCT05260073)
- Testing
- Tirbanibulin
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Almirall, S.A.
Keratosis, Actinic
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm^2 on the face or balding scalp.
- Trial name
- NCT05279131
- Testing
- Tirbanibulin ointment 1%
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.
- Trial name
- NCT02838628
- Testing
- 50 mg of KX2-391 Ointment 1%
- Where
- 16 sites in United States
- Volunteers
- 168 people
- Sponsor
- Almirall, S.A.
Actinic Keratoses
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
This Phase III study is designed to evaluate the efficacy and safety of KX2-391 Ointment in adult participants when applied to an area of skin containing 4-8 stable, clinically typical Actinic Keratosis (AK) lesions on the face…
- Trial name
- AK003 (NCT03285477)
- Testing
- KX2-391 Ointment 1%
- Where
- 30 sites in United States
- Volunteers
- 351 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
This Phase III study was designed to evaluate the efficacy and safety of KX2-391 Ointment 1% in adult participants when applied to an area of skin containing 4-8 stable, clinically typical actinic keratosis (AK) lesions on the…
- Trial name
- NCT03285490
- Testing
- KX2-391 Ointment 1%
- Where
- 30 sites in United States
- Volunteers
- 351 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
This study will evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of ACZONE Gel, 7.5% administered topically once-daily for 12 weeks in 9 to 11 year-olds with acne vulgaris.
- Trial name
- NCT02959970
- Testing
- dapsone gel
- Where
- 20 sites in United States
- Volunteers
- 100 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
- Trial name
- NCT02320149
- Testing
- Sarecycline
- Where
- 57 sites in United States
- Volunteers
- 968 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris
To evaluate the safety and effectiveness of 3 strengths of P005672-HCl compared to placebo for the treatment of moderate to severe facial acne vulgaris.
- Trial name
- NCT01628549
- Testing
- 50 mg P005672-HCl, 100 mg P005672-HCl
- Where
- 38 sites in United States
- Volunteers
- 285 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
To evaluate the efficacy and safety of an approximate 1.5 mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
- Trial name
- NCT02322866
- Testing
- Sarecycline
- Where
- 57 sites in United States
- Volunteers
- 1,034 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral sarecycline in the long-term treatment of participants with moderate to severe facial acne vulgaris.
- Trial name
- NCT02413346
- Testing
- Sarecycline
- Where
- 56 sites in United States
- Volunteers
- 490 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
- Trial name
- NCT01974141
- Testing
- Dapsone Gel, Dapsone Gel Vehicle
- Where
- 2 sites in United States, Canada
- Volunteers
- 2,102 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris
This study will assess the safety and efficacy of dapsone gel versus vehicle control in patients with acne vulgaris.
- Trial name
- NCT01974323
- Testing
- Dapsone Gel, Dapsone Gel Vehicle
- Where
- 3 sites in United States, Canada
- Volunteers
- 2,238 people
- Sponsor
- Almirall, S.A.
Chronic Obstructive Pulmonary Disease (COPD)
Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients
Preference study: Genuair vs HandiHaler inhalers in COPD patients.
- Trial name
- NCT01385696
- Testing
- Genuair® (Almirall S.A.), HandiHaler® (Boehringer Ingelheim's)
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 130 people
- Sponsor
- Almirall, S.A.